GemVax & KAEL has filed for expanded access of its U.S. Food and Drug Administration (FDA) investigational new drug (IND) application for GV1001, its experimental treatment for Alzheimer’s disease. The company is seeking to include additional investigational groups in its clinical development program. The filing comes following positive results of a Phase 2 clinical trial (NCT03184467) of the therapeutic candidate, conducted in Korea. “It gives us the confidence to expand the range of indications targeted…
You must be logged in to read/download the full post.
The post GemVax Seeks Expanded Access for Mild Alzheimer’s for Planned GV1001 US Trial appeared first on BioNewsFeeds.